Min Huang

List of Publications by Year
in descending order

62 papers	3,458 citations	159585 30 h-index	144013 57 g-index
66 all docs	66 docs citations	66 times ranked	6246 citing authors

#	Article	IF	Citations
1	Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. Acta Pharmaceutica Sinica B, 2018, 8, 552-562.	12.0	294
2	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	8.7	255
3	Natural Products in Cancer Therapy: Past, Present and Future. Natural Products and Bioprospecting, 2021, 11, 5-13.	4.3	237
4	Inactivation of Murine Usp1 Results in Genomic Instability and a Fanconi Anemia Phenotype. Developmental Cell, 2009, 16, 314-320.	7.0	217
5	Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell, 2018, 175, 186-199.e19.	28.9	166
6	Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Research, 2017, 27, 784-800.	12.0	149
7	Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells. Molecular Cancer Therapeutics, 2013, 12, 2651-2662.	4.1	137
8	Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. Cancer Cell, 2016, 30, 459-473.	16.8	117
9	The FANCM/FAAP24 Complex Is Required for the DNA Interstrand Crosslink-Induced Checkpoint Response. Molecular Cell, 2010, 39, 259-268.	9.7	114
10	Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase. Clinical Cancer Research, 2017, 23, 6267-6278.	7.0	94
11	Chimmitecan, a Novel 9-Substituted Camptothecin, with Improved Anticancer Pharmacologic Profiles In vitro and In vivo. Clinical Cancer Research, 2007, 13, 1298-1307.	7.0	91
12	One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibodyâ€“drug conjugates. Organic and Biomolecular Chemistry, 2016, 14, 9501-9518.	2.8	88
13	Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. Nature Communications, 2019, 10, 2701.	12.8	82
14	The Machadoâ€“Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53. PLoS Biology, 2016, 14, e2000733.	5.6	66
15	Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Molecular Cancer Therapeutics, 2008, 7, 1440-1449.	4.1	64
16	Inhibition of the Nedd8 System Sensitizes Cells to DNA Interstrand Cross-linking Agents. Molecular Cancer Research, 2012, 10, 369-377.	3.4	61
17	JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification. Cancer Research, 2015, 75, 4923-4936.	0.9	61
18	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry, 2019, 62, 3898-3923.	6.4	60

#	Article	IF	Citations
19	Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 2227-2244.	6.4	55
20	Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells. Journal of Cell Biology, 2017, 216, 409-424.	5.2	52
21	A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metabolism, 2019, 30, 1107-1119.e8.	16.2	52
22	c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. Cancer Research, 2015, 75, 4548-4559.	0.9	47
23	Identification of Epigallocatechin-3- Gallate as an Inhibitor of Phosphoglycerate Mutase 1. Frontiers in Pharmacology, 2017, 8, 325.	3.5	45
24	Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology, 2017, 65, 1948-1962.	7.3	43
25	Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. Journal of Medicinal Chemistry, 2022, 65, 1243-1264.	6.4	42
26	Ataxin-3 promotes genome integrity by stabilizing Chk1. Nucleic Acids Research, 2017, 45, 4532-4549.	14.5	40
27	FANCD2 and REV1 cooperate in the protection of nascent DNA strands in response to replication stress. Nucleic Acids Research, 2015, 43, 8325-8339.	14.5	38
28	A new nuclease member of the FAN club. Nature Structural and Molecular Biology, 2010, 17, 926-928.	8.2	35
29	Discovery and Optimization of 4,5-Diarylisoxazoles as Potent Dual Inhibitors of Pyruvate Dehydrogenase Kinase and Heat Shock Protein 90. Journal of Medicinal Chemistry, 2014, 57, 9832-9843.	6.4	34
30	Polî· O-GlcNAcylation governs genome integrity during translesion DNA synthesis. Nature Communications, 2017, 8, 1941.	12.8	34
31	Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors. European Journal of Medicinal Chemistry, 2014, 87, 765-781.	5.5	33
32	Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. Cancer Letters, 2017, 406, 105-115.	7.2	32
33	Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration. Journal of Cancer, 2017, 8, 1943-1951.	2.5	31
34	A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Molecular Cell, 2021, 81, 4076-4090.e8.	9.7	31
35	NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion. Acta Pharmaceutica Sinica B, 2022, 12, 2859-2868.	12.0	31
36	Lactate Dehydrogenase B Is Associated with the Response to Neoadjuvant Chemotherapy in Oral Squamous Cell Carcinoma. PLoS ONE, 2015, 10, e0125976.	2.5	30

#	Article	IF	Citations
37	c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors. Clinical Cancer Research, 2017, 23, 974-984.	7.0	27
38	Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. DNA Repair, 2011, 10, 1203-1212.	2.8	26
39	Mismatch repair protein MSH2 regulates translesion DNA synthesis following exposure of cells to UV radiation. Nucleic Acids Research, 2013, 41, 10312-10322.	14.5	25
40	RBM45 competes with HDAC1 for binding to FUS in response to DNA damage. Nucleic Acids Research, 2017, 45, 12862-12876.	14.5	25
41	REV1 promotes PCNA monoubiquitination through interacting with ubiquitinated RAD18. Journal of Cell Science, 2016, 129, 1223-33.	2.0	24
42	Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation. Molecular Cell, 2022, 82, 1297-1312.e8.	9.7	24
43	RNA-splicing factor SART3 regulates translesion DNA synthesis. Nucleic Acids Research, 2018, 46, 4560-4574.	14.5	23
44	Fragment-based drug discovery of triazole inhibitors to block PDEÎ´-RAS protein-protein interaction. European Journal of Medicinal Chemistry, 2019, 163, 597-609.	5.5	20
45	Acetylation at lysine 71 inactivates superoxide dismutase 1 and sensitizes cancer cells to genotoxic agents. Oncotarget, 2015, 6, 20578-20591.	1.8	20
46	SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Research, 2022, 32, 638-658.	12.0	19
47	Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 721-725.	2.2	17
48	Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors. European Journal of Medicinal Chemistry, 2021, 216, 113333.	5.5	16
49	Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacologica Sinica, 2014, 35, 89-97.	6.1	15
50	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy. Journal of Medicinal Chemistry, 2022, 65, 4818-4831.	6.4	15
51	Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors. Science China Life Sciences, 2017, 60, 94-97.	4.9	14
52	SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo. Cancer Letters, 2014, 351, 143-150.	7.2	13
53	The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma. Tumor Biology, 2016, 37, 479-489.	1.8	12
54	Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy. European Journal of Medicinal Chemistry, 2018, 148, 140-153.	5.5	12

#	Article	IF	Citations
55	Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2). Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2600-2604.	2.2	11
56	6â€²Methoxyethylaminoâ€numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. FASEB Journal, 2017, 31, 5453-5465.	0.5	9
57	Parkin regulates translesion DNA synthesis in response to UV radiation. Oncotarget, 2017, 8, 36423-36437.	1.8	8
58	iTRAQ-based chromatin proteomic screen reveals CHD4-dependent recruitment of MBD2 to sites of DNA damage. Biochemical and Biophysical Research Communications, 2016, 471, 142-148.	2.1	7
59	SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-METâ€“Dependent Neoplastic Effects and Exerts Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 36-45.	2.5	6
60	Harnessing Genomic Stress for Antitumor Immunity. Antioxidants and Redox Signaling, 2021, 34, 1128-1150.	5.4	5
61	DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro. Acta Pharmacologica Sinica, 2015, 36, 1266-1276.	6.1	3
62	Discovery of PHGDH inhibitors by virtual screening and preliminary structureâ€“activity relationship study. Bioorganic Chemistry, 2022, 121, 105705.	4.1	3